Correlating ISEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients on Nivolumab

被引：0
|
作者：
Park, W. [1 ]
Lopes, G. [1 ]
Kwon, D. [2 ]
Florou, V. [1 ]
Chae, Y. K. [3 ]
Warsch, J. [4 ]
Ishkanian, A. [5 ]
Jahanzeb, M. [6 ]
Mudad, R. [1 ]
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Hematol & Oncol, Miami, FL USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med Biostat & Bioinformat, Miami, FL USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Dev Therapeut Program, Chicago, IL 60611 USA
[4] Univ Miami, Sylvester Comprehens Canc Ctr, Radiol, Miami, FL USA
[5] Univ Miami, Sylvester Comprehens Canc Ctr, Radiat Oncol, Miami, FL USA
[6] Univ Miami, Sylvester Comprehens Canc Ctr, Med Oncol, Miami, FL USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Tumor mutation burden; biomarker; Nivolumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.07-025
引用
收藏
页码：S2004 / S2005
页数：2
相关论文
共 50 条
  • [31] Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
    Costantini, Adrien
    Julie, Catherine
    Dumenil, Coraline
    Helias-Rodzewicz, Zofia
    Tisserand, Julie
    Dumoulin, Jennifer
    Giraud, Violaine
    Labrune, Sylvie
    Chinet, Thierry
    Emile, Jean-Francois
    Leprieur, Etienne Giroux
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [32] Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy
    Fenizia, Francesca
    Pasquale, Raffaella
    Roma, Cristin
    Bergantino, Francesca
    Iannaccone, Alessia
    Normanno, Nicola
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 668 - 677
  • [33] Nivolumab for treating non-small cell lung cancer
    Guibert, Nicolas
    Mazieres, Julien
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (12) : 1789 - 1797
  • [34] Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer
    Huang, Lan
    Li, Li
    Zhou, Yingxu
    Yang, Zhaoyang
    Wang, Meng
    Gao, Yina
    Yang, Yang
    Yang, Fang
    Liu, Bao
    Hong, Xuan
    Chen, Gongyan
    JOURNAL OF CANCER, 2020, 11 (24): : 7137 - 7145
  • [35] Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
    Chen, Hao
    Chong, Wei
    Wu, Qian
    Yao, Yueliang
    Mao, Min
    Wang, Xin
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [36] Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer
    Hida, Toyoaki
    Nishio, Makoto
    Nogami, Naoyuki
    Ohe, Yuichiro
    Nokihara, Hiroshi
    Sakai, Hiroshi
    Satouchi, Miyako
    Nakagawa, Kazuhiko
    Takenoyama, Mitsuhiro
    Isobe, Hiroshi
    Fujita, Shiro
    Tanaka, Hiroshi
    Minato, Koichi
    Takahashi, Toshiaki
    Maemondo, Makoto
    Takeda, Koji
    Saka, Hideo
    Goto, Koichi
    Atagi, Shinji
    Hirashima, Tomonori
    Sumiyoshi, Naoki
    Tamura, Tomohide
    CANCER SCIENCE, 2017, 108 (05) : 1000 - 1006
  • [37] Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
    Leprieur, Etienne Giroux
    Herbretau, Guillaume
    Dumenil, Coraline
    Julie, Catherine
    Giraud, Violaine
    Labrune, Sylvie
    Dumoulin, Jennifer
    Tisserand, Julie
    Emile, Jean-Francois
    Blons, Helene
    Chinet, Thierry
    ONCOIMMUNOLOGY, 2018, 7 (05):
  • [38] Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients
    Sarocchi, Matteo
    Grossi, Francesco
    Arboscello, Eleonora
    Bellodi, Andrea
    Genova, Carlo
    Dal Bello, Maria Giovanna
    Rijavec, Erika
    Barletta, Giulia
    Rossi, Giovanni
    Biello, Federica
    Ghigliotti, Giorgio
    Canepa, Marco
    Mussap, Michele
    Brunelli, Claudio
    Spallarossa, Paolo
    ONCOLOGIST, 2018, 23 (08) : 936 - 942
  • [39] Smoking Status Is Not a Replacement Biomarker for Tumor Mutation Burden in Non-Small Lung Cancer
    Sharpnack, M.
    Cho, J. H.
    Johnson, T.
    Otterson, G.
    Shields, P.
    Huang, K.
    Carbone, D.
    He, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S444 - S445
  • [40] Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden
    Muto, Satoshi
    Ozaki, Yuki
    Yamaguchi, Hikaru
    Mine, Hayato
    Takagi, Hironori
    Watanabe, Masayuki
    Inoue, Takuya
    Yamaura, Takumi
    Fukuhara, Mitsuro
    Okabe, Naoyuki
    Matsumura, Yuki
    Hasegawa, Takeo
    Osugi, Jun
    Hoshino, Mika
    Higuchi, Mitsunori
    Shio, Yutaka
    Nanamiya, Hideaki
    Imai, Jun-Ichi
    Isogai, Takao
    Watanabe, Shinya
    Suzuki, Hiroyuki
    ONCOLOGY LETTERS, 2021, 21 (03)
12345